Characterization of Beta-Lactam Resistance in Clinical Pseudomonas aeruginosa and Escherichia coli Isolates from Trinidad and Tobago

Antibiotics are the quiet guardians of modern medicine, allowing doctors to treat infections that would once have been fatal. Among the most powerful of these drugs are the beta-lactams, a vast family that includes penicillins, cephalosporins, and carbapenems. These medicines work by attacking the very wall that bacteria build to protect themselves, causing the cell to collapse. However, bacteria are relentless adapters. Over time, many have learned to produce special enzymes, essentially molecular scissors, that cut the beta-lactam ring open before the drug can do its job. This ability to neutralize the medicine is known as resistance, and it turns once-effective treatments into useless chemicals. Two of the most common bacteria causing serious infections in hospitals are Escherichia coli and Pseudomonas aeruginosa. While E. coli is often found in the gut and can cause urinary or bloodstream infections, P. aeruginosa is an opportunistic invader that thrives in hospital environments, particularly affecting patients with weakened immune systems or those on breathing machines. When these two bacteria become resistant to beta-lactams, the options for treatment shrink dangerously, making it vital to understand exactly how they are surviving.

In Trinidad and Tobago, a team of researchers set out to map this evolving threat within their local hospitals. They gathered a large collection of bacterial samples taken from patients between 2021 and 2024. The group included 154 samples of E. coli and 132 samples of P. aeruginosa, collected from various sources such as urine, blood, wound swabs, and spinal fluid. The first step was to see how these bacteria behaved in the lab. The scientists exposed the bacteria to different antibiotics and watched to see if the drugs stopped them from growing. They found that resistance was already a significant problem. About one-third of the E. coli samples could not be stopped by second- and third-generation cephalosporins, a common class of antibiotics. Even more concerning, nearly one-quarter of the P. aeruginosa samples were immune to carbapenems, which are often considered the last line of defense against stubborn infections.

The researchers then compared the two bacteria to see if one was more dangerous than the other regarding these specific drugs. They discovered a clear difference in how the two organisms handled the most powerful antibiotics. While E. coli showed resistance to carbapenems in about 9 percent of cases, P. aeruginosa was resistant in nearly 24 percent of cases. This meant that the P. aeruginosa bacteria were roughly three times more likely to be immune to these last-resort drugs than their E. coli counterparts. The difference was not a small fluctuation but a statistically significant gap, suggesting that P. aeruginosa in this region has developed a particularly strong shield against the most potent treatments available.

To understand the machinery behind this resistance, the team took a closer look at the genetic code of a smaller group of the resistant bacteria. They selected 25 resistant samples of each species and used a technique called polymerase chain reaction to search for specific genes known to produce the molecular scissors that destroy antibiotics. They looked for six different types of genes: TEM, SHV, CTX, KPC, OXA, and IMP. The results revealed that the two bacteria use different genetic toolkits to achieve the same dangerous outcome. In the E. coli samples, the most common gene found was CTX, which appeared in more than half of the tested samples. They also found TEM, SHV, and OXA genes, but they found no trace of the KPC or IMP genes.

The story was different for P. aeruginosa. While it also carried the CTX, SHV, and OXA genes, it possessed two additional types that were completely absent in the E. coli samples: KPC and IMP. The presence of the IMP gene is particularly notable because it codes for a metallo-beta-lactamase, a type of enzyme that is exceptionally good at breaking down carbapenems. This gene was found in 12 percent of the P. aeruginosa samples. The researchers noted that finding the gene does not automatically prove the bacteria are using it right now, but its presence is a clear warning sign that the potential for high-level resistance exists in the local population. The fact that P. aeruginosa carried these extra genetic tools helps explain why it was more frequently resistant to the strongest antibiotics than E. coli.

The study also highlighted that the genetic picture is not the whole story. In many cases, the bacteria were resistant to the drugs even though the specific genes the researchers were looking for were not found. This suggests that the bacteria are using other methods to survive, such as changing the structure of their outer walls to keep drugs out or pumping the antibiotics out before they can work. These mechanisms are complex and varied, meaning that a simple test for a few genes cannot always predict how a bacterium will behave. The researchers emphasized that while they found clear evidence of these resistance genes, the full scope of the problem likely includes many other genetic factors that were not part of their search.

Ultimately, this work provides a crucial snapshot of the bacterial landscape in Trinidad and Tobago. It confirms that resistance to beta-lactam antibiotics is widespread and that the two major bacteria causing hospital infections are evolving in distinct ways. E. coli relies heavily on a specific set of genes to resist common antibiotics, while P. aeruginosa has access to a broader and more dangerous arsenal, including the ability to produce enzymes that destroy the most powerful drugs. The detection of the IMP gene in P. aeruginosa is a specific finding that demands attention, as it signals the presence of a highly effective resistance mechanism. The authors conclude that keeping a close watch on these bacteria is essential. They recommend that future monitoring should not just look at whether the bacteria are resistant, but should also use advanced genetic sequencing to track exactly which tools they are using. Only by understanding the full range of these survival strategies can doctors and public health officials hope to stay ahead of the bacteria and protect the effectiveness of the medicines that save lives.